Chief Scientific Officer Roberts M Scot sale 10,182 shares of Altimmune Inc. [ALT]

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Altimmune Inc. shares valued at $122,184 were sold by Roberts M Scot on Jul 05. At $12.00 per share, Roberts M Scot sold 10,182 shares. The insider’s holdings dropped to 8,305 shares worth approximately $97168.5 following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Roberts M Scot sold 26,982 shares, netting a total of over 323,784 in proceeds. Following the sale of shares at $12.00 each, the insider now holds 17,700 shares.

Before that, Roberts M Scot had sold 5,462 shares from its account. In a trade valued at $65,546, the Chief Scientific Officer traded Altimmune Inc. shares for $12.00 each. Upon closing the transaction, the insider’s holdings decreased to 5,462 shares, worth approximately $0.21 million.

Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early June. As of February 11, 2021, Guggenheim has initiated its “Buy” rating for ALT. Earlier on December 14, 2020, Jefferies initiated its rating. Their recommendation was “a Buy” for ALT stock.

Analyzing ALT’s Price Performance

On Thursday, Altimmune Inc. [NASDAQ: ALT] rose 1.65% to $11.70. The stock’s lowest price that day was $11.62, but it reached a high of $12.27 in the same session. During the last five days, there has been a drop of approximately -1.93%. Over the course of the year, Altimmune Inc. shares have jumped approximately 27.73%. Shares of the company reached a 52-week high of $13.44 on 07/22/22 and a 52-week low of $3.83 on 05/12/22. A 50-day SMA is recorded $9.81, while a 200-day SMA reached $8.31. Nevertheless, trading volume fell to 1.2 million shares from 0.43 million shares the previous day.

Support And Resistance Levels for Altimmune Inc. (ALT)

According to the 24-hour chart, there is a support level at 11.46, which, if violated, would cause prices to drop to 11.21. In the upper region, resistance lies at 12.11. The next price resistance is at 12.51. RSI (Relative Strength Index) is 52.87 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.21, which suggests the price will decrease in the coming days. Percent R is at 52.89%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Altimmune Inc. subject to short interest?

Stocks of Altimmune Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -1.76 million shares to 4.4 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 6.16 million shares. A decline of -40.0% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.31 of the overall float, the days-to-cover ratio (short ratio) decline to 2.31.

Which companies own the most shares of Altimmune Inc. (ALT)?

According to TIAA-CREF Investment Management L filings, the company currently owns 3,159,176 shares, which is about 7.31% of the total ALT shares outstanding. The investor’s shares have appreciated by 949,372 from its previous 13-F filing of 2209804.0 shares. Avidity Partners Management LP acquire a 3.62% interest valued at $33.52 million while BlackRock Fund Advisors sold a -16,702 stake. A total of 973,744 shares of Altimmune Inc. were sold by Tang Capital Management LLC during the quarter, and 88,667 were bought by The Vanguard Group, Inc. In its current portfolio, Ardsley Advisory Partners LP holds 1,353,000 shares valued at $15.83 million.

In terms of Altimmune Inc. share price expectations, FactSet research, analysts set an average price target of $23.14 in the next 12 months, up nearly 117.2% from the previous closing price of $11.51. Analysts anticipate Altimmune Inc. stock to reach $30.00 by 2022, with the lowest price target being $12.00. In spite of this, 7 analysts ranked Altimmune Inc. stock as a Buy at the end of 2022. On November 12, 2020, B. Riley Securities assigned a price target of “a Buy” to the stock and reiterated coverage with a $28.


Please enter your comment!
Please enter your name here